» Articles » PMID: 11751186

Changes in Spirometry over Time As a Prognostic Marker in Patients with Duchenne Muscular Dystrophy

Overview
Specialty Critical Care
Date 2001 Dec 26
PMID 11751186
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Duchenne muscular dystrophy (DMD) causes a progressive impairment of muscle function leading to hypercapnic respiratory failure. Most studies of respiratory function in DMD have been cross-sectional rather than longitudinal, and these data have not been related to survival. We retrospectively studied 58 patients with DMD with at least 2 yr of follow-up spirometry and known vital status. Spirometry was abnormal at entry: median FEV(1) 1.60 L (range 0.4 to 2.6 L), FVC 1.65 L (range 0.45 to 2.75 L), FVC 64% predicted (range 29 to 97%). Individual rates of change of vital capacity varied, with a median annual change of -0.18 L (range 0.04 to -0.74 L), -8.0% predicted FVC (range 2 to -39%). During the study 37 patients died; the median age of death, calculated by Kaplan-Meier analysis, was 21.5 yr (range 15 to 28.5 yr). The age when vital capacity fell below 1 L was a strong marker of subsequent mortality (5-yr survival 8%). The maximal vital capacity recorded and its rate of decline (however expressed) predicted survival time. Repeated spirometric measurement provides a simple and relatively powerful means of assessing disease progression in these patients and should be considered when planning treatment trials.

Citing Articles

Respiratory pathology in the mdx/utrn -/- mouse: A murine model for Duchenne Muscular Dystrophy (DMD).

Hernandez Rodriguez M, Biswas D, Slyne A, Lee J, Scarrow E, Abdelbarr S PLoS One. 2025; 20(2):e0316295.

PMID: 39919154 PMC: 11805407. DOI: 10.1371/journal.pone.0316295.


Clinical Profile and Pulmonary Function of Pediatric Patients with Duchenne Muscular Dystrophy at a Tertiary Government Hospital.

Arquillo M, Layug E, Lozada M, Bautista K, Calotes-Castillo L Acta Med Philipp. 2025; 58(21):49-59.

PMID: 39758300 PMC: 11694038. DOI: 10.47895/amp.vi0.7975.


A New Perspective on Drugs for Duchenne Muscular Dystrophy: Proposals for Better Respiratory Outcomes and Improved Regulatory Pathways.

Birnkrant D, Black J, Sheehan D, Baker H, DiBartolo M, Katz S Paediatr Drugs. 2024; 27(2):143-159.

PMID: 39707120 PMC: 11829838. DOI: 10.1007/s40272-024-00673-3.


The Relevance of Spinal Muscular Atrophy Biomarkers in the Treatment Era.

Maretina M, Koroleva V, Shchugareva L, Glotov A, Kiselev A Biomedicines. 2024; 12(11).

PMID: 39595052 PMC: 11591959. DOI: 10.3390/biomedicines12112486.


Long-term outcomes in children with riboflavin transporter deficiency and surveillance recommendations.

Fennessy J, Cornett K, Donlevy G, McKay M, Burns J, Menezes M Dev Med Child Neurol. 2024; 67(3):405-415.

PMID: 39252496 PMC: 11794669. DOI: 10.1111/dmcn.16083.